BIOLactis

BioLactis is a South Korean biotechnology company specializing in the development of microbiome-based therapeutics and functional probiotics. Established in 1998, the company focuses on the isolation and characterization of lactic acid bacteria to address various health conditions, including inflammatory diseases and metabolic disorders. Their lead therapeutic candidate, BL-11, is being developed for the treatment of atopic dermatitis through gut-skin axis modulation. BioLactis also maintains a commercial presence in the nutraceutical market, providing specialized probiotic strains for functional foods. The company's research efforts are centered on leveraging the therapeutic potential of the human microbiome to create next-generation biotherapeutics.